Mineralocorticoids, hypertension, and cardiac fibrosis

Journal of Clinical Investigation

Volumn 93, Issue 6, 1994, Pages 2578-2583

  Young, Morag ^a   Fullerton, Meryl ^a   Dilley, Rodney ^a   Funder, John ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

aldosterone; deoxycorticosterone; interstitial fibrosis; perivascular fibrosis; RU486

Indexed keywords

ALDOSTERONE; CORTICOSTERONE; DEOXYCORTICOSTERONE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE REGULATION; HEART MUSCLE FIBROSIS; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 0028290539     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI117269     Document Type: Article

References (25)

1. McEwen, B. S., L. T. Lambdin, T. C. Rainbow, and A. F. DeNicola. 1986. Aldosterone effects on salt appetite in adrenalectomized rats. Neuroendocrinology. 43:38-43.
2. Arriza, J. L., C. Weinberger, T. Glaser, B. L. Handelin, D. E. Housman, and R. M. Evans. 1987. Cloning of the human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science (Wash. DC). 237:268-275.
3. Krozowski, Z. S., and J. W. Funder. 1983. Renal mineralocorticoid receptors and hippocampal corticosterone binding species have identical intrinsic steroid specificity. Proc. Natl. Acad. Sci. USA. 80:6056-6060.
4. Funder, J. W., P. T. Pearce, R. Smith, and A. I. Smith. 1988. Mineralocorticoid action: target-tissue specificity is enzyme, not receptor-mediated. Science (Wash. DC). 242:583-585.
5. Edwards, C. R. W., P. M. Stewart, D. Burt, M. A. McIntyre, E. R. de Kloet, L. Brett, W. S. Sutanto, and C. Monder. 1988. Localization of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet. ii:986-989.
6. Brilla, C. G., and K. T. Weber. 1992. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J. Lab. Clin. Med. 120:893-901.
7. Brilla, C. G., L. S. Matsubara, and K. T. Weber. 1993. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell. Cardiol. 25:563-575.
8. Brilla, C. G., G. Zhou, and K. T. Weber. 1992. Aldosterone-mediated stimulation of collagen synthesis in cultured cardiac fibroblasts. Proc. 14th Sci. Meeting, Intl. Soc. Hypertens P23 (Abstr.).
9. Chiariello, M., G. Ambrosio, M. Cappelli-Bigazzi, P. Perrone-Filardi, F. Brigante, and C. Sifola. 1986. A biochemical method for the quantitation of myocardial scarring after experimental coronary artery occlusion. J. Mol. Cell. Cardiol. 18:283-290.
10. Dobler, P. C., and M. S. Spach. 1987. Picrosirius red staining of cardiac muscle following phosphomolybdic acid treatment. Stain Technol. 62:23-26.
11. Muller, A. E., L. M. Cruz-Orive, P. Gehr, and E. R. Weibel. 1981. Comparison of two subsampling methods for electron microscopic morphometry. J. Microsc. (Oxf.). 123:35-49.
12. Ludbrook, J. 1991. On making multiple comparisons in clinical and experimental pharmacology and physiology. Clin. & Exp. Pharm. Physiol. 18:379-392.
13. Gomez-Sanchez, E. P. 1991. What is the role of the central nervous system in mineralocorticoid hypertension? Am. J. Hypertens. 4:374-381.
14. Gomez-Sanchez, E. P., M. T. Venkataraman, D. Thwaites, and C. Fort. 1990 Intracerebroventricular infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am. J. Physiol. 258:E649-E653.
15. Gomez-Sanchez, E. P., C. M. Fort, and C. E. Gomez-Sanchez. 1990. Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension. Am. J. Physiol. 258:E482-E484.
16. Funder, J. W., P. T. Pearce, K. Myles, and L. P. Roy. 1990. Apparent mineralocorticoid excess, pseudohypoaldosteronism and urinary electrolyte excretion: towards a redefinition of "mineralocorticoid" action. FASEB (Fed. Am. Soc. Exp. Biol.) J. 4:3234-3238.
17. Funder, J. W. 1991. A la recherche du temps perdu. In Aldosterone: Fundamental Aspects. J.-P. Bonvalet, N. Farman, M. Lombes, and M.-E. Rafestin-Oblin, editors. John Libbey Eurotext Limited, Montrouge, France. 77-83.
18. Hierholzer, K., M. Schoneshofer, H. Siebe, D. Tsiakiras, and P. Weskamp. 1984. Corticosteroid metabolism in isolated rat kidney in vitro. Pfluegers Arch. Eur. J Physiol. 400:363-371.
19. Mercer, W. R., and Z. S. Krozowski. 1992. Localization of an 11β-hydroxysteroid dehydrogenase activity to the distal nephron of the rat kidney. Evidence for the existence of two species of dehydrogenase in the rat kidney. Endocrinology. 130:540-543.
20. Marks, R., J. Barlow, and J. W. Funder. 1982. The mechanisms of steroidinduced vasoconstriction: glucocorticoid antagonist studies. J. Clin. Endocrinol. & Metab 54:1075-1077.
21. Zaini, A., P. Pearce, and J. W. Funder. 1986. High affinity aldosterone binding in rat liver - a re-evaluation, Clin Exp. Pharm. Physiol. 14:39-45.
22. Sakai, R. R., V. Lakshmi, C. Monder, and B. S. McEwen. 1992. Immunocytochemical localization of 11β hydroxysteroid dehydrogenase in hippocampus and other brain regions of the rat. J. Neuroendocrinol 4:101-106.
23. Slight, S., V. K. Ganjam, D. Nonneman, and K. T. Weber. 1992. Hydroxysteroid dehydrogenase activity in cultured cardiac fibroblasts versus aortic endothelial cells. Clin. Res. 40:683a. (Abstr.)
24. Naray-Fejes-Toth, A., and G. Fejes-Toth. 1990. Glucocorticoid receptors mediate mineralocorticoid-like effects in cultured collecting duct cells. Am. J. Physiol. 259:F672-F678.
25. Jonat, C., H. J. Rahmsdorf, K.-K. Park, A. C. B. Cato, S. Gebel, H. Ponta, and P. Herrlich. 1990. Antitumor promotion and antiinflammation: down modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormones. Cell. 62:1189-1204.